We conjectured that direct activation of mTORC1 by RAS and SLC3A2 is the primary mode of oncogenic RAS signaling in MM, and that RAS may not fully engage the MAPK pathway unless mTORC1 signaling is blocked. The gene discussed is SLC3A2; the disease is Miyoshi myopathy.